<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The presence of the JAK2 V617F mutation is now part of clinical diagnostic algorithms, and JAK2 status is routinely assessed when BCR/ABL- <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MPNs) are suspected </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to evaluate performance of 3 screening and 1 quantitative method for JAK2 V617F detection </plain></SENT>
<SENT sid="2" pm="."><plain>For the study, 43 samples (27 bone marrow aspirates and 16 peripheral blood samples) were selected </plain></SENT>
<SENT sid="3" pm="."><plain>The screening assays were the JAK2 Activating Mutation Assay (InVivoScribe, San Diego, CA), JAK2 MutaScreen kit (Ipsogen, Luminy Biotech, Marseille, France), and a home-brew melting curve analysis method </plain></SENT>
<SENT sid="4" pm="."><plain>Ipsogen's JAK2 MutaQuant assay was used for quantification of mutant and <z:mp ids='MP_0002169'>wild-type</z:mp> alleles </plain></SENT>
<SENT sid="5" pm="."><plain>The limit of detection was 1% for the kit-based screening methods and 10% for the melting curve method </plain></SENT>
<SENT sid="6" pm="."><plain>The JAK2 MutaQuant assay demonstrated analytic sensitivity of 0.01% </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 4 methods detected cases of BCR/ABL- MPNs and gave negative results with BCR/ABL+ <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and <z:mpath ids='MPATH_458'>normal</z:mpath> cases </plain></SENT>
</text></document>